scholarly journals Reply to: “Microvascular Breakdown Due to Retinal Neurodegeneration in Ataxias”

2022 ◽  
Author(s):  
Christopher A. Turski ◽  
Gabrielle N. Turski ◽  
Jennifer Faber ◽  
Stefan J. Teipel ◽  
Frank G. Holz ◽  
...  
Keyword(s):  
Retinal Neurodegeneration

Retinal microglia polarization in diabetic retinopathy

2021 ◽  
Vol 38 ◽  
Author(s):  
Xin Li ◽  
Zi-Wei Yu ◽  
Hui-Yao Li ◽  
Yue Yuan ◽  
Xin-Yuan Gao ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Diabetic Retinopathy ◽  
Cytokine Production ◽  
Immune Cell ◽  
Microvascular Disease ◽  
Retinal Diseases ◽  
Microglia Polarization ◽  
Retinal Microglia ◽  
The Central Nervous System ◽  
Retinal Neurodegeneration

Abstract Microglia, the main immune cell of the central nervous system (CNS), categorized into M1-like phenotype and M2-like phenotype, play important roles in phagocytosis, cell migration, antigen presentation, and cytokine production. As a part of CNS, retinal microglial cells (RMC) play an important role in retinal diseases. Diabetic retinopathy (DR) is one of the most common complications of diabetes. Recent studies have demonstrated that DR is not only a microvascular disease but also retinal neurodegeneration. RMC was regarded as a central role in neurodegeneration and neuroinflammation. Therefore, in this review, we will discuss RMC polarization and its possible regulatory factors in early DR, which will provide new targets and insights for early intervention of DR.

Alzheimers Disease and Retinal Neurodegeneration

2010 ◽  
Vol 7 (1) ◽  
pp. 3-14 ◽  
Author(s):  
L. Guo ◽  
J. Duggan ◽  
M. Cordeiro
Keyword(s):  
Alzheimers Disease ◽  
Retinal Neurodegeneration

scholarly journals Retinal Neurodegeneration in Diabetic Patients Without Diabetic Retinopathy

2016 ◽  
Vol 57 (14) ◽  
pp. 6455 ◽  
Author(s):  
Joana Tavares Ferreira ◽  
Marta Alves ◽  
Arnaldo Dias-Santos ◽  
Lívio Costa ◽  
Bruno Oliveira Santos ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Diabetic Patients ◽  
Retinal Neurodegeneration

scholarly journals Deletion of arginase 2 attenuates neuroinflammation in an experimental model of optic neuritis

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0247901
Author(s):  
Amritha A. Candadai ◽  
Fang Liu ◽  
Abdelrahman Y. Fouda ◽  
Moaddey Alfarhan ◽  
Chithra D. Palani ◽  
...  
Keyword(s):  
Optic Neuritis ◽  
Experimental Model ◽  
Axonal Degeneration ◽  
Wild Type ◽  
Autoimmune Encephalomyelitis ◽  
Optic Nerves ◽  
Clinical Presentations ◽  
Retinal Neurodegeneration ◽  
The Impact ◽  
Experimental Autoimmune

Vision impairment due to optic neuritis (ON) is one of the major clinical presentations in Multiple Sclerosis (MS) and is characterized by inflammation and degeneration of the optic nerve and retina. Currently available treatments are only partially effective and have a limited impact on the neuroinflammatory pathology of the disease. A recent study from our laboratory highlighted the beneficial effect of arginase 2 (A2) deletion in suppressing retinal neurodegeneration and inflammation in an experimental model of MS. Utilizing the same model, the present study investigated the impact of A2 deficiency on MS-induced optic neuritis. Experimental autoimmune encephalomyelitis (EAE) was induced in wild-type (WT) and A2 knockout (A2-/-) mice. EAE-induced cellular infiltration, as well as activation of microglia and macrophages, were reduced in A2-/- optic nerves. Axonal degeneration and demyelination seen in EAE optic nerves were observed to be reduced with A2 deletion. Further, the lack of A2 significantly ameliorated astrogliosis induced by EAE. In conclusion, our findings demonstrate a critical involvement of arginase 2 in mediating neuroinflammation in optic neuritis and suggest the potential of A2 blockade as a targeted therapy for MS-induced optic neuritis.

scholarly journals Evaluation of retinal nerve fibre layer thickness as a possible measure of diabetic retinal neurodegeneration in the EPIC-Norfolk Eye Study

2021 ◽  
pp. bjophthalmol-2021-319853
Author(s):  
Sidra Zafar ◽  
Kristen A Staggers ◽  
Jie Gao ◽  
Yao Liu ◽  
Praveen J Patel ◽  
...  
Keyword(s):  
Nerve Fibre ◽  
Structural Changes ◽  
Retinal Nerve Fibre Layer ◽  
Diabetes Diagnosis ◽  
Fibre Layer ◽  
Diabetes Status ◽  
Retinal Neurodegeneration ◽  
Nerve Fibre Layer ◽  
Diabetic Retinal Neurodegeneration ◽  
The Relationship

Background/aimsMarkers to clinically evaluate structural changes from diabetic retinal neurodegeneration (DRN) have not yet been established. To study the potential role of peripapillary retinal nerve fibre layer (pRNFL) thickness as a marker for DRN, we evaluated the relationship between diabetes, as well as glycaemic control irrespective of diabetes status and pRNFL thickness.MethodsLeveraging data from a population-based cohort, we used general linear mixed models (GLMMs) with a random intercept for patient and eye to assess the association between pRNFL thickness (measured using GDx) and demographic, systemic and ocular parameters after adjusting for typical scan score. GLMMs were also used to determine: (1) the relationship between: (A) glycated haemoglobin (HbA1c) irrespective of diabetes diagnosis and pRNFL thickness, (B) diabetes and pRNFL thickness and (2) which quadrants of pRNFL may be affected in participants with diabetes and in relation to HbA1c.Results7076 participants were included. After controlling for covariates, inferior pRNFL thickness was 0.94 µm lower (95% CI −1.28 µm to −0.60 µm), superior pRNFL thickness was 0.83 µm lower (95% CI −1.17 µm to −0.49 µm) and temporal pRNFL thickness was 1.33 µm higher (95% CI 0.99 µm to 1.67 µm) per unit increase in HbA1c. Nasal pRNFL thickness was not significantly associated with HbA1c (p=0.23). Similar trends were noted when diabetes was used as the predictor.ConclusionSuperior and inferior pRNFL was significantly thinner among those with higher HbA1c levels and/or diabetes, representing areas of the pRNFL that may be most affected by diabetes.

scholarly journals HIF inhibitor topotecan has a neuroprotective effect in a murine retinal ischemia-reperfusion model

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e7849 ◽  
Author(s):  
Hiromitsu Kunimi ◽  
Yukihiro Miwa ◽  
Yusaku Katada ◽  
Kazuo Tsubota ◽  
Toshihide Kurihara
Keyword(s):  
Intraocular Pressure ◽  
Visual Evoked Potentials ◽  
Retinal Thickness ◽  
Neuroprotective Effect ◽  
Ischemia Reperfusion ◽  
Hypoxia Inducible Factor ◽  
Retinal Ischemia ◽  
Retinal Ganglion ◽  
Neuroprotective Effects ◽  
Retinal Neurodegeneration

Purpose The therapeutic approach for retinal ganglion cell (RGC) degeneration has not been fully established. Recently, it has been reported that hypoxia-inducible factor (HIF) may be involved with retinal neurodegeneration. In this study, we investigated neuroprotective effects of a HIF inhibitor against RGC degeneration induced in a murine model of retinal ischemia-reperfusion (I/R). Methods Eight-weeks-old male C57/BL6J mice were treated with intraperitoneal injection of a HIF inhibitor topotecan (1.25 mg/kg) for 14 days followed by a retinal I/R procedure. Seven days after the I/R injury, the therapeutic effect was evaluated histologically and electrophysiologically. Results The increase of HIF-1α expression and the decrease of retinal thickness and RGC number in I/R were significantly suppressed by administration of topotecan. Impaired visual function in I/R was improved by topotecan evaluated with electroretinogram and visual evoked potentials. Conclusions Topotecan administration suppressed HIF-1a expression and improved RGC survival resulting in a functional protection against retinal I/R. These data indicated that the HIF inhibitor topotecan may have therapeutic potentials for RGC degeneration induced with retinal ischemia or high intraocular pressure.

scholarly journals Detecting retinal neurodegeneration in people with diabetes: Findings from the UK Biobank

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0257836
Author(s):  
Roomasa Channa ◽  
Kyungmoo Lee ◽  
Kristen A. Staggers ◽  
Nitish Mehta ◽  
Sidra Zafar ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Glycated Hemoglobin ◽  
Retinal Thickness ◽  
Self Report ◽  
Inner Plexiform Layer ◽  
Uk Biobank ◽  
Fiber Layer ◽  
Cross Sectional ◽  
Retinal Neurodegeneration ◽  
The Uk

Importance Efforts are underway to incorporate retinal neurodegeneration in the diabetic retinopathy severity scale. However, there is no established measure to quantify diabetic retinal neurodegeneration (DRN). Objective We compared total retinal, macular retinal nerve fiber layer (mRNFL) and ganglion cell-inner plexiform layer (GC-IPL) thickness among participants with and without diabetes (DM) in a population-based cohort. Design/setting/participants Cross-sectional analysis, using the UK Biobank data resource. Separate general linear mixed models (GLMM) were created using DM and glycated hemoglobin as predictor variables for retinal thickness. Sub-analyses included comparing thickness measurements for patients with no/mild diabetic retinopathy (DR) and evaluating factors associated with retinal thickness in participants with and without diabetes. Factors found to be significantly associated with DM or thickness were included in a multiple GLMM. Exposure Diagnosis of DM was determined via self-report of diagnosis, medication use, DM-related complications or glycated hemoglobin level of ≥ 6.5%. Main outcomes and measures Total retinal, mRNFL and GC-IPL thickness. Results 74,422 participants (69,985 with no DM; 4,437 with DM) were included. Median age was 59 years, 46% were men and 92% were white. Participants with DM had lower total retinal thickness (-4.57 μm, 95% CI: -5.00, -4.14; p<0.001), GC-IPL thickness (-1.73 μm, 95% CI: -1.86, -1.59; p<0.001) and mRNFL thickness (-0.68 μm, 95% CI: -0.81, -0.54; p<0.001) compared to those without DM. After adjusting for co-variates, in the GLMM, total retinal thickness was 1.99 um lower (95% CI: -2.47, -1.50; p<0.001) and GC-IPL was 1.02 μm lower (95% CI: -1.18, -0.87; p<0.001) among those with DM compared to without. mRNFL was no longer significantly different (p = 0.369). GC-IPL remained significantly lower, after adjusting for co-variates, among those with DM compared to those without DM when including only participants with no/mild DR (-0.80 μm, 95% CI: -0.98, -0.62; p<0.001). Total retinal thickness decreased 0.40 μm (95% CI: -0.61, -0.20; p<0.001), mRNFL thickness increased 0.20 μm (95% CI: 0.14, 0.27; p<0.001) and GC-IPL decreased 0.26 μm (95% CI: -0.33, -0.20; p<0.001) per unit increase in A1c after adjusting for co-variates. Among participants with diabetes, age, DR grade, ethnicity, body mass index, glaucoma, spherical equivalent, and visual acuity were significantly associated with GC-IPL thickness. Conclusion GC-IPL was thinner among participants with DM, compared to without DM. This difference persisted after adjusting for confounding variables and when considering only those with no/mild DR. This confirms that GC-IPL thinning occurs early in DM and can serve as a useful marker of DRN.

Sign in / Sign up

Export Citation Format

Share Document